Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 17:49:54 Source:sportViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:The fightback begins: Boss of London's Queen Mary University tells pro
Next:Dodgers acquire pitcher Yohan Ramírez from Mets for cash
You may also like
- Four people killed in a house explosion in southwestern Missouri
- George Clooney beams as he rings in his 63rd birthday with cake and balloons alongside co
- Iowa facility that mistreated residents with intellectual disabilities nears closure
- Cease, 2 relievers combine on 1
- A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it
- California girl, 14, is charged with the murder of human trafficking non
- Man indicted in killing of Laken Riley, a Georgia case at the center of national immigration debate
- Slow to expand, internet casino gambling is the future of US betting, industry execs say
- What's next for Iran after death of its president in crash?